Tasigna licence extended

Nilotinib (Tasigna) can now be prescribed as a first-line option for chronic myeloid leukaemia (CML).

The BCR-ABL tyrosine kinase inhibitor has been approved for the treatment of newly diagnosed Philadelphia-chromosome-positive CML in the chronic phase. In an open-label Phase III study in this setting, patients treated with nilotinib 300mg twice daily showed a significantly higher major molecular response rate (as assessed by levels of circulating BCR-ABL transcripts) than those who received imatinib 400mg twice daily (44.3% vs 22.3%; p<0.0001).

The new indication comes with a new 150mg capsule presentation, to allow dosing at 300mg twice daily. The recommended dose for second-line treatment (in patients resistant to or intolerant of imatinib) remains 400mg twice daily.

View Tasigna drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more